Poly-N-acetyl-β-(1,6)-glucosamine (PNAG) (PNAG)

Poly-N-acetyl-β-(1,6)-glucosamine (PNAG), also known as polysaccharide intercellular adhesin (PIA), is a critical cell-surface exopolysaccharide produced by Staphylococcus epidermidis and various other bacterial pathogens (Mack et al., 1996). It serves as a primary structural component of the biofilm matrix, facilitating cell-to-cell adhesion and providing a protective shield against the host's innate immune system, including phagocytosis and complement-mediated killing (Cerca et al., 2007). In clinical settings, PNAG is a major virulence factor in chronic and device-related infections, such as those involving prosthetic joints and intravenous catheters (Rupp et al., 1999). As a therapeutic target, PNAG is highly attractive due to its conservation across multiple Gram-positive and Gram-negative species, including S. aureus, E. coli, and K. pneumoniae (Cywes-Bentley et al., 2013). Experimental treatments include monoclonal antibodies like F598, which bind to PNAG to promote opsonophagocytic killing, and enzymatic agents like Dispersin B that degrade the biofilm structure (Itoh et al., 2005). Vaccines targeting PNAG are also under investigation, aiming to provide broad-spectrum protection against biofilm-forming pathogens by inducing high titers of protective antibodies (Maira-Litrán et al., 2004).

Other names

Polysaccharide intercellular adhesinPIAPoly-N-acetylglucosamineβ-1,6-linked N-acetylglucosamine polymerPoly-N-acetyl-beta-(1,6)-glucosamine

Monoclonal antibodies targeting PNAG facilitate opsonophagocytic killing (OPK) by host immune cells (Cywes-Bentley et al., 2013). Enzymatic agents like Dispersin B act by hydrolyzing the β-1,6-glycosidic linkages within the PNAG polymer, leading to the degradation and dispersal of the bacterial biofilm (Itoh et al., 2005). Vaccines aim to induce high titers of IgG antibodies that bind to the deacetylated epitopes of PNAG to provide protective immunity (Maira-Litrán et al., 2004).